NCT00943527已完成不适用
Molecular Breast Imaging: Effect of Menstrual Cycle, Hormone Therapy, and Tamoxifen on Tc-99m Sestamibi Uptake in the Breast.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 110
- 试验地点
- 1
研究概览
简要总结
This study is to examine the effects of menstrual cycle, hormone therapy, and the use of tamoxifen on Tc-99m sestamibi uptake.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 35 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •age 35-45
- •have regular menstrual cycles as defined by having menstrual cycle length of 25-31 days, with menstrual flow of 2-7 days, and no intermenstrual spotting or bleeding.
- •have had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.
排除标准
- •currently using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase inhibitors
- •have a personal history of any cancer, except non-melanomatous skin cancer
- •unable to understand and sign the consent form
- •pregnant or lactating
- •physically unable to sit upright and still for 30 minutes
- •Inclusion Criteria:
- •scheduled to begin one of the following regimens of HT:
- •Any dosage of any formulation of systemic estrogen therapy in the setting of a prior hysterectomy
- •Any dosage of continuous estrogen plus monthly, cyclic progesterone therapy where the progesterone therapy is the oral, micronized formulation
- •had a negative screening mammogram within one year prior to the MBI studies that is available for comparison.
- •Exclusion Criteria:
- •have a personal history of any cancer, except non-melanomatous skin cancer
- •unable to understand and sign the consent form
- •pregnant or lactating
- •physically unable to sit upright and still for 30 minutes
- •Inclusion Criteria:
- •scheduled to begin treatment with tamoxifen Or are currently being treated with tamoxifen (for > 1 month) and have had an MBI scan performed prior to its initiation
- •have had or will have the following test performed at Mayo Clinic: #87966, Cytochrome P450 2D6 genotyping for Tamoxifen Hormonal Therapy
- •have had a screening or diagnostic mammogram within one year of the MBI studies that is available for comparison.
- •Exclusion Criteria:
- •are using or have used any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones), any estrogen receptor modulating drugs other than tamoxifen, or any aromatase inhibitors from the time of 1 month prior to the first MBI until completion of the second MBI.
- •have been treated or will be undergoing treatment with systemic chemotherapy or external radiation beam therapy to the breast from the time of 6 months prior to the first MBI until the completion of the second MBI.
- •unable to understand and sign the consent form
- •pregnant or lactating
- •physically unable to sit upright and still for 30 minutes
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Managing Temporomandibular Disorder (TMD) SymptomsTemporomandibular Joint DisordersNCT00237042University of Washington252
Unknown
不适用
Tamoxifen Pharmacogenetics in Asian Breast Cancer WomenPoisoning by, Adverse Effect of and Underdosing of TamoxifenNCT01181518Inje University1,000
已完成
不适用
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast CancerBreast CancerNCT00086749Northwestern University53
已完成
不适用
Hormonal Causes of Menstrual-Related Mood DisordersMood DisordersDepressionNCT00100360National Institute of Mental Health (NIMH)22
Unknown
3 期
Tamoxifen Citrate in Patients With Breast CancerBreast CancerNCT00963209Centre Hospitalier Universitaire Vaudois140